ACTUATE CORP, and PORTAL SOFTWARE INC. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and ...

At the end of August 2024, long-time video game fans grew excited about the potential development of Portal 3. The anticipation was sparked by posts on X from an account displaying the name Gabe ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing ...

Nearly a year after its release, I’ve seen virtually no marketing for the PlayStation Portal. Yet it’s selling like hotcakes. I had to find out what I was missing out on. Is this a product of ...

I did not think for a second I was going to be impressed by the PlayStation Portal, Sony's small-screen Remote Play solution for the PS5. With Remote Play already working great on tablets and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Elraglusib is a Class-LeadingGSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer Trials Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s ...

Actuate Therapeutics has won Food and Drug Administration orphan-drug designation for its lead investigational drug product in a group of rare cancerous tumors. Actuate on Wednesday said the ...

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...